Devonian Health Group Inc. (DVHGF) Research

Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.

Market snapshot

Symbol
DVHGF
Price
$10.65
Day change
0.00%
Market cap
$42.0M
P/E ratio
-4.71x
52-week range
4.266-10.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 5 days

Peer companies

  • Eco-Growth Strategies Inc. (ECGS)
  • Hemostemix Inc. (HMTXF)
  • HOOKIPA Pharma Inc. (HOOK)
  • EOM Pharmaceuticals Holdings, Inc. (IMUC)
  • Inhibitor Therapeutics, Inc. (INTI)
  • Algorae Pharmaceuticals Limited (LVCLF)
  • Nymox Pharmaceutical Corporation (NYMXF)
  • Oxford BioDynamics Plc (OXBOF)

Open Devonian Health Group Inc. (DVHGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.